Division of Biology, Kansas State University, Manhattan, Kansas, USA.
Beckman Research Institute of City of Hope, Duarte, California, USA.
J Med Virol. 2023 Nov;95(11):e29244. doi: 10.1002/jmv.29244.
Cervical cancers are the fourth most common and most deadly cancer in women worldwide. Despite being a tremendous public health burden, few novel approaches to improve care for these malignancies have been introduced. We discuss the potential for proliferating cell nuclear antigen (PCNA) inhibition to address this need as well as the advantages and disadvantages for compounds that can therapeutically inhibit PCNA with a specific focus on cervical cancer.
宫颈癌是全球女性中第四常见和最致命的癌症。尽管它给公共卫生带来了巨大负担，但很少有新的方法来改善这些恶性肿瘤的治疗。我们讨论了增殖细胞核抗原 (PCNA) 抑制的潜力，以满足这一需求，以及具有特定治疗抑制 PCNA 作用的化合物的优缺点，重点是宫颈癌。
